中國醫藥(600056.SH):子公司3個產品擬中標第八批全國藥品集採
格隆匯3月30日丨中國醫藥(600056.SH)公佈,2023年3月29日,公司下屬子公司海南通用三洋藥業有限公司(簡稱“三洋藥業”)參加了第八批全國藥品集中採購的投標。根據聯合採購辦公室發佈的全國藥品集中採購擬中選結果公示顯示,三洋藥業通過仿製藥質量和療效一致性評價的產品注射用哌拉西林鈉他唑巴坦鈉、注射用頭孢噻肟鈉、醋酸阿託西班注射液擬中標該次集中採購。
三洋藥業該次擬中標的注射用哌拉西林鈉他唑巴坦鈉2021年度營業收入約為2.2億元,2022年度未經審計營業收入約為3.83億元;注射用頭孢噻肟鈉和醋酸阿託西班注射液2021年度和2022年度無銷售。該次擬中標的三個產品中標數量收入預計約為2.16億元,約佔公司2021年度經審計的營業收入總額的0.6%,預計不會對公司收入產生較大影響。
公司表示,該次集中採購是國家組織的第八批藥品集中帶量採購,採購週期中,醫療機構將優先使用該次集中採購中選品種,並確保完成約定採購量。若三洋藥業後續簽訂採購合同並實施後,將有利於進一步擴大相關產品的銷售,提高市場佔有率,促進三洋藥業有關產品的市場開拓,提升公司的品牌影響力,對公司的未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.